Neuroscientific Biopharmaceuticals Ltd has released a press release.
Ethics Approval Granted for Early-Phase Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- HREC Submission for early-phase Clinical Trial
- Positive safety result supports advance to clinical trials
- New data demonstrates EmtinB activity in autoimmune diseases
- NSB 1HY22 Key Activity Highlights
- Successful completion of key studies in lead up to Phase I
Later from Neuroscientific Biopharmaceuticals
- Positive results in MS animal study
- First Subject Recruited for Early-Phase Clinical Trial
- HREC Submission for Phase I Clinical Trial
- NeuroScientific releases FY2022 Results
- 2022 Annual Report and Appendix 4E
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals